Coronavirus | Indian ‘double mutant’ strain named B.1.617

First variant to have 2 mutations that enable it to evade antibodies and increase inffectivity

Updated - December 02, 2021 10:48 pm IST

Published - April 08, 2021 10:06 pm IST - NEW DELHI

A lab assistant uses a pipette to prepare coronavirus RNA for sequencing. File

A lab assistant uses a pipette to prepare coronavirus RNA for sequencing. File

The ‘double mutant’ virus that scientists had flagged last month as having a bearing on the spread of the pandemic in India, has a formal scientific classification: B.1.617.

Other than a place on the coronavirus’s evolutionary history, it also brings focus on the role the variant may be playing in the pandemic, which is now seeing nearly 100,000 fresh infections daily and a conflict between the Centre and some States on the availability of vaccines.

Also read: How significant is the new 'double mutant' variant?

The variant is common in India — how much in every state though is unclear — and has a couple of defining mutations, E484Q and L425R, that enable them to become more infectious as well as evade antibodies. Though these mutations have individually been found in several other coronavirus variants, the presence of both these mutations together have been first found in some coronavirus genomes from India.

“This is a homegrown variant and widely exported internationally,” said a scientist involved in the sequencing studies but who declined to be identified.

Certain variants of the coronavirus, for instance, B.1.1.7 and B.1.351 — have been termed the ‘United Kingdom’ and ‘South Africa’ variant respectively because they have mutations associated with large spikes in these countries or reduce the efficacy of vaccines and are termed ‘Variants of Concern (VOC)’.

‘Not yet of concern’

According to a note from the INSACOG, the consortium of laboratories that’s sequencing a sample of genomes from coronavirus patients in India, B.1.617 was first detected in India on December 7, 2020. Though now present in at least eight countries, nearly 70% of the genome sequences that have the mutations characterising B.1.617 and submitted to the global database GISAID (Global Initiative on Sharing Avian Influenza Data) are from India. This is followed by the United Kingdom (23%), Singapore (2%) and Australia (1%).


“That suggests that this variant is fairly common in India. It is worrying because the mutations E484Q and L452R are linked to increased infectivity. It’s been linked to 20% of the cases in Maharashtra but we have to also see the role of the variant (from further genome studies) in say West Bengal, Uttar Pradesh where there are massive crowds from elections, the Kumbh Mela,” said Shahid Jameel, virologist and Director, Trivedi School of Biosciences, Ashoka University.

An explainer note by the INSACOG on the significance of the mutations says that it has as many as 15 ‘lineage defining mutations’. Other than the two mutations, there is also has a third significant mutation, P614R. All three concerning mutations are on the spike protein, the operative part of the coronavirus that binds to receptor cells of the body.

Resistant to T cells

L452R, some studies show, could even make the coronavirus resistant to T cells, that are class of cells necessary to target and destroy virus-infected cells. They are different from antibodies that are useful in blocking coronavirus particles and preventing it from proliferating.

India has not yet conducted studies on how vaccine efficacy is influenced by variants, except for limited laboratory trials, but international studies have shown reduced efficacy of vaccines — particularly those by Pfizer, Moderna and Novavax — to certain variants. However, the vaccines continue to be significantly protective in spite of this.

So far, only three global VOCs have been identified: the U.K. variant, the South African and the Brazilian (P.1) lineage. Of the 10,787 samples from international passengers, 771 instances of these VOCs have been identified in 18 States of the country, according to a statement from the Health Ministry in March.

A scientist associated with the INSACOG said vaccine makers should now be accounting for the variations in the spike protein in designing future vaccine. “That's the real purpose of genomic analysis. To design appropriate vaccines but so far there are hardly such studies out of India,” the scientist pointed out.

Genome variation studies from Kerala have revealed the presence of other mutations associated with the ability to help the coronavirus evade neutralising antibodies. The N440K mutation that is associated with immune escape has been found in 123 samples from 11 districts. This was earlier found in 33% of samples from Andhra Pradesh, and in 53 of 104 samples from Telangana. This has also been reported from 16 other countries, including the U.K., Denmark, Singapore, Japan and Australia.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.